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ABSTRAK
Pesakit myeloid leukemia kronik (CML) bermutasi BCR-ABL T315I sering 
menunjukkan kelangsungan hidup keseluruhan yang lebih pendek berbanding 
mereka yang tidak mempunyai mutasi tersebut. Tujuan kajian ini adalah untuk 
mengenalpasti prevalens mutasi T315I dikalangan pesakit CML yang menunjukkan 
rintangan terhadap imatinib mesylate (IM) dan membandingkan fasa penyakit serta 
kelangsungan hidup antara pesakit CML bermutasi T315I dan yang tidak. Enam 
puluh pesakit CML yang telah dirawat dengan IM untuk sekurang-kurangnya 18 
bulan dan tindak-balas rawatan mereka direkodkan. Analisis mutasi T315I telah 
dilakukan menggunakan allele khusus oligonucleotide reverse transcriptase 
polymerase chain reaction (RT-PCR) diikuti oleh teknik direct sequencing. 42 
(70%) orang pesakit didapati mempunyai rintangan terhadap IM dan daripada para 
pesakit tersebut, lima (12%) telah dikesan mempunyai mutasi T315I. Keseluruhan 
kelangsungan hidup untuk pesakit CML yang menunjukkan rintangan terhadap IM 
dengan mutasi T315I adalah 96 bulan (95% CI:54-138) berbanding mereka yang 
tidak mempunyai mutasi iaitu 84 bulan (95% CI:48-120) walaupun nilai ini tidak 
signifikan secara statistik [nilai p=0.43]). Kajian ini menunjukkan kadar kekerapan 
mutasi T315I (12%) di kalangan pesakit kohort kami adalah lebih tinggi. Median 
kelangsungan hidup keseluruhan bagi mereka yang mempunyai mutasi T315I 
adalah lebih panjang berbanding daripada mereka yang tidak mempunyai mutasi. 
Kajian lebih lanjut melibatkan bilangan pesakit yang lebih ramai adalah diperlukan 
untuk mengesahkan pemerhatian tersebut.
146
Med & Health Jun 2019;14(1): 145-156 Mardziah M. et al.
Kata kunci: BCR ABL, chronic myeloid leukemia, mutasi T315I
ABSTRACT
Chronic myeloid leukemia (CML) patients who have BCR-ABL T315I mutation, 
usually present in the advance phase of the disease with overall survival (OS) shorter 
than those without the mutation. This study aimed to determine the prevalence 
of T315I mutation amongst imatinib mesylate (IM) resistant CML patients and to 
compare the OS between T315I-mutated and non-T315I-mutated patients. Sixty 
consecutive CML patients who were treated with IM for at least 18 months and 
their treatment responses, were recorded. The mutation analysis was done using 
allele-specific oligonucleotide reverse transcriptase-polymerase chain reaction 
(RT-PCR) assay followed by direct sequencing technique. Forty-two patients (70%) 
were found to have IM-resistance. Five out of 42 patients had detectable T315I 
mutation. Median OS of IM-resistant T315I-mutated patients was 96 months 
(95% CI:54-138) compared to 84 months (95% CI:48-120) in non T315I-mutated 
patients, although this was found to be statistically insignificant (p = 0.43). The 
present study showed a higher prevalence of T315I mutation as compared to a few 
local studies. Median OS of T315I-mutated patients were observed to be longer 
than non-T315-mutated patients. Further studies encompassing larger cohort of 
patients are required to confirm this finding.
Keywords: BCR ABL, chronic myeloid leukemia, T315I mutation
site or other regions of the tyrosine 
kinase domain is the most dominant 
mechanism of resistance (Valent et al. 
2008). These BCR-ABL mutations were 
reported to occur in approximately 
50% of patients who developed 
resistance to imatinib mesylate (IM) 
(Jabbour et al. 2006). These mutations 
inhibit IM or other TKI drugs from 
binding to the ATP binding site of the 
tyrosine kinase domain, thus inhibiting 
the tyrosine kinase activity (Vaidya et 
al. 2011).
 Among all the mutations in the 
BCR-ABL kinase domain, the greatest 
degree of resistance was associated 
with the T315I mutation and point 
INTRODUCTION
Despite the good response of chronic 
myeloid leukemia (CML) patients 
to tyrosine kinase inhibitors (TKI), 
studies have shown that they do 
eventually develop resistance towards 
the treatment (Vaidya et al. 2011). 
Resistance to TKIs were reported in 
some CML patients in chronic phase 
(CP) and in most patients in more 
advanced phases of the disease 
(accelerated and blast phase) (Soverini 
et al. 2007). 
 Detection of several different point 
mutations in the amino acids of the 
BCR-ABL tyrosine kinase ATP binding 
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mutations in the P-loop domain 
which are G250E, Q252H, Y253F and 
E255K/V (Vaidya et al. 2011). T315I 
mutation was reported to occur in 7% 
of CML patients with IM resistance 
(Chahardouli et al. 2013). It is also 
called the mutation of the gatekeeper 
position as it prevents binding of TKIs. 
It represents a substitution of the amino 
acid isoleucine for threonine in the 
BCR-ABL kinase domain. Threonine 
315 forms a crucial hydrogen bond 
with IM and the absence of an 
oxygen atom in the substituted 
isoleucine prevented bond formation. 
Additionally, the bulkier isoleucine 
was predicted to induce a steric clash 
with IM, which led to the designation 
of the 315 residues (Gorre et al. 2001). 
T315I mutation was found to affect a 
common ABL kinase contact residue 
and confers complete resistance to 
all known ATP-competitive BCR-ABL 
inhibitors (Chahardouli et al. 2013).
 Accordingly, T315I mutation is more 
commonly detected in patients with 
progression of the disease phase /and 
is associated with severe IM resistance, 
disease progression and poor clinical 
outcome. This mutation was also 
shown to have poor overall survival 
(OS) and progression free survival (Kim 
et al. 2009). 
 The aim of the present study was 
to determine the presence of T315I 
mutations in CML patients with 
IM-resistance using allele-specific 
oligonucleotide-reverse transcriptase 
polymerase chain reaction (ASO-RT-
PCR) method which was subsequently 
confirmed by direct sequencing 
method. We investigated the difference 
between the demographic data of 
CML patients with and without T315I 
mutation and correlated the mutation 
status with OS. 
MATERIALS AND METHODS
STUDY DESIGN
In this comparative cross-sectional 
study, 60 consecutive patients who 
were diagnosed from January 2002 
until May 2014 were recruited from 
Universiti Kebangsaan Malaysia 
Medical Centre (UKMMC). The 
patients were in different (chronic, 
accelerated and blast) phases of the 
disease and were being treated with 
IM with doses between 200-800 mg/
day for at least 18 months. 
 The basic demographic, disease 
characteristics and treatment details 
were retrieved from patients’ medical 
records. For each patient, diagnosis 
was confirmed by hematological, 
cytogenetics and molecular analysis 
of the bone marrow. Hematological, 
cytogenetic and molecular responses 
were evaluated every 3 months to 
determine the response to IM treatment 
using peripheral blood. 
 Patients who developed primary 
and secondary resistance according 
to the hematologic, cytogenetic and 
molecular response criteria in the 
2013 European LeukemiaNet (ELN) 
guidelines were identified (Baccarani 
et al. 2013).
T315I MUTATION ANALYSIS
RNA was extracted from samples 
obtained from peripheral blood or bone 
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marrow which contained leukocytes 
using RiboPureTM-Blood Kit (Ambion 
USA). From the RNA, complementary 
DNA (cDNA) was generated using 
SuperScript II cDNA synthesis kit 
(Invitrogen, USA) according to 
manufacturer’s instructions. 
 T315I mutation was detected using 
allele specific-polymerase chain 
reaction (AS-PCR) method. Three sets 
of primers which consist of mutant 
primers, forward (5’-gcc ccc gtt cta tat 
cat aat-3’) and reverse (5’-gga tga agt 
ttt tct tct cca g-3’), wild type primers 
with forward (5’-tgg ttc atc atc att caa 
cgg tgg-3’) reverse (5’-gtt ccc gta ggt 
cat gaa ctc ag- 3’) as well as internal 
control primers with forward (5’-gtg 
ggg cgc ccc agg cac ca-3’) and reverse 
(5’-gtc ctt aat gtc acg cac gat ttc-3’) 
were used. All of these sequences were 
adapted from the previously published 
studies (Roche et al. 2002; Auewarakul 
et al. 2006).
 The reaction took place in a thermal 
cycler (ABI 9700, Applied Biosystems 
Geneamp, USA) in a reaction mixture 
containing 1.0 μL of cDNA, 0.625 unit 
of Taq DNA polymerase (Invitrogen, 
USA), 14 pmol of mutant primers, 6 
pmol of wild type primers, 1 pmol of 
internal control primers, 2.5 mmol/L 
MgCl2, 0.2 mmol/L of Deoxynucleotide 
Triphosphate (dNTP), 3% Dimethyl 
sulfoxide (DMSO) and 0.625 unit of 
Taq DNA polymerase (Invitrogen, 
USA).
 The thermal profile used for 
amplification were as follows: 95˚C of 
initial denaturation for 5 minutes (min), 
followed by 35 cycles of denaturation 
for 45 seconds at 94˚C, primer 
annealing at 57˚C for 30 seconds, 
extension for 1 minutes at 72˚C, and 
final extension for 5 minutes at 72˚C. 
These sets of PCR primers generate 
three PCR products of mutant T315I, 
wild type T315I, and internal control 
band at 158, 374 and 540 basepairs 
(bp), respectively. The products were 
visualized under ultraviolet light by 
electrophoresis on a 1.5% agarose 
gel stained using Olerup SSP® Gel 
Red stains. Ten RNA samples from 
non-leukemic patients were used as a 
normal control and samples with only 
added distilled water without cDNA, 
was used as a negative control. 
DNA SEQUENCING METHOD
Bidirectional sequencing method was 
used to detect T315I mutation for ASO-
RT-PCR-positive patients (Branford et 
al. 2002). Samples of RT-PCR-negative 
patients were also sequenced for 
comparison. The samples were purified 
using PCR purification kit (QIAquick, 
Qiagen) and then sequenced using 
BigDye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, 
Foster City, CA, USA). Finally, the 
sequences were compared with the 
wild-type ABL sequence (GenBank 
accession number NM 005157.5) and 
analyzed using Finch TV analyzer.
STATISTICAL ANALYSIS
Statistical analysis was conducted 
using Mann-Whitney U and Kruskal-
Wallis tests to assess the differences 
of measurable variation among the 
patients. Kaplan-Meier survival curves 
were plotted for analysis between 
presence of mutation and the time from 
149
T315I Mutation Detection in CML Patients Med & Health Jun 2019;14(1): 145-156
diagnosis to last follow-up or death and 
the differences were estimated using 
the log rank test. The p value was two-
sided and the level of significance was 
chosen at 0.05. 
RESULTS
BASELINE CHARACTERISTICS OF 
THE CML PATIENTS
The basic demographic data (gender, 
race and age) of the 60 CML patients 
were shown in Table 1. The median 
age of the patients was 45 years (range: 
29.5-61 years) and the median time 
from diagnosis to last follow-up/death 
was 72 months (range: 18-204 months). 
Out of the 60 patients, 42 (70%) were 
resistant to IM in which primary and 
secondary resistant patients were 29 
and 13, respectively (Table 1). 
TREATMENT RESPONSE IN IM-
RESISTANT PATIENTS 
Thirty-two (76.2%) patients were able 
to achieve complete haematological 
remission (CHR) after 18 months of 
Total number of CML patients 60
Gender:
  Male 38 (63.3%)
  Female 22 (36.7%)
Race:
  Malay 38 (63.3%)
  Chinese 15 (25%) 
  Indian 4 (6.7%)
  Others 3 (5.0%)
Median age at diagnosis, years 45 (29.5-61)
Disease phase:
  CP 56 (93.3%)
  AP 4 (6.7%)
  BP 0
Median time from diagnosis to last follow-up/death, months 72 (18-204)
Response to IM treatment:
  Not IM-resistant 18 (30%)
  IM-resistant 42 (70%)
    -Primary resistance:
       No CHR 4 (6.7%)
       No CyR 25 (41.7%)
    -Secondary resistance:
       Loss of CHR 2 (3.33%)
       Loss of CyR 11 (18.3%)
Table 1: Baseline characteristic of all CML patients and response to IM treatment (CP=Chronic phase; 
AP=accelerated phase; BC=blast crisis, CHR=complete hematological remission; CyR=cytogenetic 
remission)
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treatment with IM. Out of the 32 
patients, 4 (9.5%) achieved complete 
cytogenetic remission (CCyR) while 16 
(38.1%) had incomplete cytogenetic 
response at the time of analysis (Table 
2). The demographic data of IM-
resistant patients are shown in Table 3. 
T315I MUTATION ANALYSIS AND 
DIRECT SEQUENCING 
Qualitative results of T315I mutation 
analysis using gel electrophoresis 
could be seen in Figures 1A and 1B. 
In both figures, lane 2, 4, 13, 6 and 
7 represent the patients who had 
the T315I mutation which showed 
the presence of three distinct bands 
including mutant T315I band (indicate 
T315I mutation), wild type T315I band 
and internal control band at 158, 374 
and 540 base pairs, respectively. The 
rest of the unlabelled lanes represent 
the patients who did not have the 
mutation and showed the presence 
of wild type T315I band and internal 
control band at 374 and 540 base 
pairs, respectively. Lane 14 and lane 8 
represented the non-template control 
or negative control while lane 15 and 
lane 9 represented normal control.
 This mutation was later confirmed 
by direct sequencing analysis showing 
the changes made by C1308T where 
an ‘ACT’ coding for Threonine mutate 
to an ‘ATT’ coding for Isoleucine 
(T315I) in exon 7 (Figure 1C). 
SUMMARY OF IM-RESISTANT CML 
PATIENTS WITH T315I MUTATION
Figure 1C: DNA sequencing analysis showing 
the changes made by C1308T whre an 'ACT' 
coding for Threonine mutate to an 'ATT' coding 
for Isoleucine (T315I) in exon 7. WT (Wild type) 
represent the nucleotide sequence of a normal 
patient while MT (mutant type) represents the 
nucleotide sequence of the patient who is 
positive for T315I mutation
Figure 1A and 1B: Gel electrophoresis results 
of patients with T315I mutation. In both figures, 
lane 2,4, 13, 6 and 7 represent the patients who 
have the T315I mutation which show presence 
of three disinct bands including mutant T315I 
band (indicate T315I mutation), wild type T315I 
band and internal control band at 158, 374 
and 540 base pairs respecticely. The rest of the 
unlabeled lanes represent the patients who do 
not have the mutation and shows presence of 
wild type T315I band and internal  control band 
at 372 and 540 base pairs respectively. Lane 14 
and lane 8 represent the non-template control 
or negative control while lane 15 and lane 9 
represent normal control
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Table 4 summarized the clinical data 
of patients with T315I mutation. Two of 
them were in accelerated phase (n=1) 
and blast crisis (n=1), respectively. 
Three achieved CHR but all never 
achieved CCyR. The two patients who 
were in advanced phase of the disease 
died from progression to blast crisis 
(n=1) and sepsis (n=1). 
 Patient 1 was a 39-year-old man 
who was diagnosed with CML in 
accelerated phase with 17% blasts 
detected in the bone marrow. His 
initial BCR-ABL copy numbers 
were 130.64%. He was started on 
hydroxyurea (HU) for 4 years before 
Total number of IM-resistant patients 42
Response to IM treatment after 18 months 
- Haematological response:
     CHR 32 (76.2%)
     No CHR 10 (23.8%)
- Cytogenetic response:
     CCyR 4 (9.5%)
     Incomplete CyR 16 (38.1)
     (No Cyr, Minimal CyR, Minor CyR, Partial CyR)
     Unknown 12 (28.6)
Table 2: Response to TKI treatment in 42 IM-resistant CML patients after 18 months follow-up 
period (CHR=complete hematological response; CyR=cytogenetic response; CCyR=complete 
cytogenetic response).





No. of patients with IM 
resistance
n=42 n=5 n=37
Age at Dx Median (Range) 44(23-56.75) 45 (41-60) 40 (23-57) 0.36
Time from diagnosis to last 
follow-up/death (months) Median (Range) 84 (48-123) 96 (54-138) 84 (48-120) 0.63
Race Malay 27 (64.3) 3 (60.0) 24 (64.9) 0.71
Chinese 11 (26.2) 2 (40.0) 9 (24.3)
Indian 3 (7.1) 0 3 (8.1)
Others 1 (2.4) 0 1 (2.7)
Gender Male 25 (59.5) 3 (60) 22 (59.5) 1.00
Female 17 (40.5) 2 (40) 15 (40.5)
Disease phase during 
analysis
AP 5 (11.9) 1 (20.0) 4 (10.8) 0.46
BC 3 (7.1) 1 (20.0) 2 (5.4)
CP 34 (81.0) 3 (60.0) 31 (83.8)
Range of dose for IM given 
per day
400-800mg 200-800mg
Table 3: Demographic data and disease phase in 42 IM-resistant CML patients and the prevalence 
of T315I mutation in these patients(AP=accelerated phase; BC=blast crisis; CP=chronic phase).
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the availability of IM therapy. He 
failed to achieve hematological and 
cytogenetic response after 12 months 
of initiation of IM and unfortunately 
developed double Ph chromosome on 
subsequent follow-up. The IM therapy 
was stopped after 3 years due to 
intolerance as he complained of severe 
headache. Eventually, he underwent 
an allogeneic stem cell transplant but 
the disease relapsed 2 months, post-
transplant. Despite donor lymphocytes 
infusion and subsequent intravenous 
Cytarabine for cytoreduction, his 
disease progressed and he succumbed 
to the disease 2 years later. 
 Patient 2 was a 45-year-old man 
who was diagnosed with CML in 
chronic phase. He was on IM 400-
800 mg daily for 4 years. As he never 
reached CCyR, the treatment was 
subsequently changed to nilotinib 200 
mg daily which she failed to respond 
to.  
 Patient 3 was a 43-year-old lady 
who was diagnosed with CML in 
chronic phase. She was treated with 
IM 400 mg daily which was switched 
to nilotinib 400 mg daily 2 years 
later when she remained in minor 
cytogenetic response. She also had 
treatment failure with nilotinib. 
 Patient 4 was a 64-year-old man 
who was diagnosed with CML in 
chronic phase. He was given 800mg 
IM per day for more than 2 years. 
However, he only remained in minimal 
CyR. As he never reached CCyR, the 
treatment was subsequently changed 
to nilotinib but unfortunately, he also 
Figure 2: This figure illustrates the overall 
survival of 42 IM resistance CML patients 
according to T315I mutation. The median OS 
among IM-resistant CML patients who have 
T315I mutation was 96 months with 1 patient 
died (n=1) while those without the mutation 
was 84 months with 3 patients (n=3) died along 
the course of the treatment. Majority of the 
patients with T315I mutation had changed to 
nilotinib after at least 2 years of IM therapy as 
they never reached CCyR









imatinib at the 
time of analysis
Time from 
diagnosis to last 
follow-up/death 
(months)
Patient 1 Male Malay 49 AP No HR, No CyR 144
Patient 2 Male Malay 55 CP CHR, Minor CyR 132
Patient 3 Female Chinese 51 CP CHR, Minor CyR 72
Patient 4 Male Malay 68 CP CHR, Minor CyR 96
Patient 5 Female Chinese 58 BC No HR, No CyR 36
Table 4: Summary of patients with T315I mutation (CP=chronic phase; AP=accelerated phase; 
BC=blast crisis; HR=hematological response; CyR=cytogenetic response; CCyR=complete 
cytogenetic response).
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showed treatment failure.
 Patient 5 was a 56-year-old lady who 
was diagnosed with CML in chronic 
phase. She was given hydroxyurea for 
11 months before starting IM therapy 
400 mg daily. She only achieved 
minimal cytogenetic response after 
1 year of treatment and transformed 
into acute myeloid leukemia with 
double Ph chromosome after 2 years 
of treatment. She eventually died due 
to blast crisis.
OVERALL SURVIVAL DATA 
ANALYSIS
The overall survival of 42 CML patients 
with IM resistant was analyzed based 
on the absence or presence of T315I 
mutation (Figure 2). The median OS 
among IM-resistant CML patients who 
had T315I mutation was 96 months 
(CI:41.25-150.75) while those without 
T315I mutation was 84 months 
(CI:72.37-102.77). Even though the 
median OS among CML patients with 
T315I mutation were longer, the results 
was statistically insignificant (p =0.43) 
as these patients may have other types 
of BCR-ABL mutation that was not 
tested in this study (Figure 2).
DISCUSSION
The aimed of the study was to analyze 
IM treatment response of CML 
patients, examine the demographic 
data of IM-resistant patients, determine 
the prevalence of T315I mutation 
in these patients and compare their 
overall survival with those without 
T315I mutation. Resistance towards 
IM therapy in CML patients has been 
associated with BCR-ABL kinase 
domain mutations (Jabbour et al. 2006). 
Among all the mutations in the BCR-
ABL kinase domain, T315I mutation 
is the most frequently identified. The 
mechanism of the mutation in T315I 
is point mutation at amino acid 315 
in which the ‘ACT’ codon that codes 
for threonine is switched to the ‘ATT’ 
codon which codes for isoleucine 
(Vaidya et al. 2011). This mutation 
inhibits IM from binding to the ATP 
binding site of the tyrosine kinase 
domain and thus inhibiting the tyrosine 
kinase activity. 
 At a median of 18 months follow-
up, 32 out of 42 (76%) patients 
achieved CHR and only 4 (12.5%) out 
of these 32 patients achieved CCyR 
(Table 2). The study showed a lower 
number of patients responding to IM 
as compared to a study by Druker et 
al. (2006) on IM efficacy in 553 CML 
patients in which 98% of patients who 
received IM achieved CHR and 87% 
achieved CCyR (Druker et al. 2006). 
Poor CyR to IM was also noted at a 
median period of 72 months from 
diagnosis to last follow-up/death 
(Table 1): 25 (41.7%) developed 
primary IM-resistance and 11 (18.3%) 
developed secondary IM-resistance 
with loss of CyR and relapsed at the 
time of analysis (Table 1). According to 
the International Randomized Study 
of Interferon and STI571 (IRIS) in 
investigating the imatinib efficacy in 
553 patients, 5% patients developed 
primary IM-resistance with failure to 
achieve a CHR after 18 months and 
the estimated rate of failure to achieve 
partial CyR was only 12% after 24 
months of follow-up. The estimated 
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rate of relapse was 10% (O’Brien et al. 
2003). Our study showed poorer CyR 
towards IM treatment which can be 
attributed to poor compliance to IM 
treatment. 
 Tables 3 summarized the 
characteristics of 42 IM-resistant CML 
patients: 25 males (59.5%) and 17 
females (40.5%). Similar findings were 
observed in a study on 60 CML patients 
with IM-resistance in Iran (Chahardouli 
et al. 2013). However, Elias et al. 
reported that in 125 CML patients with 
IM-resistance in peninsular Malaysia, 
the male to female ratio was almost 
similar (Elias et al. 2014). The median 
age at diagnosis was 44 years and it 
was predominated by Malays followed 
by Chinese, Indians and other races 
which was 27 (64.3%), 11 (26.2%), 3 
(7.1%) and 1 (2.4%), respectively. The 
racial distribution was comparable 
with the study done by Elias et al. in 
which the prevalence was dominated 
by Malays and Chinese population. 
For the disease phase, 34 (81%) were 
in chronic phase, followed by 5 (11.9%) 
and 3 (7.1%) patients in accelerated 
and blast crisis, respectively. This 
was comparable with the local study 
which showed that 75% of the 125 
IM-resistant CML patients were in 
the chronic phase (Elias et al. 2014). 
Another study by Chahardouli et al. 
showed that 71% of the 60 IM-resistant 
CML patients were reported to be in 
late chronic phase of the disease 
(Chahardouli et al. 2013). 
 In comparing the prevalence of 
T315I mutation, a study done by Elias 
et al. covering the CML patients in 
peninsular Malaysia showed presence 
of 7.2% T315I mutation. This low level 
was supported by a recent study by 
Mat Yusoff et al. on 285 IM resistant 
CML patients involving peninsular and 
east of Malaysia which demonstrate 
presence of 5.3% mutations. Our study 
reported to have 12% of patients with 
the similar mutation. However, a study 
done on 137 Korean CML patients 
with IM-resistance showed that most 
of them were in advanced phase of the 
disease: 83 (75%) patients versus only 
28 (25%) in chronic phase of the disease 
(Kim et al. 2009). The prevalence of 
T315I mutation among their patients 
is 23% which is higher compared to 
the present study and the study done 
by Elias et al. and Chahardouli et al. 
It is possible that the low frequency of 
T315I mutation identified in our study 
may be due to more CML patients who 
were in chronic phase of the disease at 
the time of analysis.
 For clinical outcome of IM-
resistance patients harboring the T315I 
mutation, previous studies showed 
that the prevalence of T315I mutation 
increased as the disease progressed 
into advanced phase (accelerated or 
blast crisis). In the study by Chahardouli 
et al., out of 4 patients with T315I 
mutation, only one of them was in 
late chronic phase of the disease and 
the patient subsequently progressed 
into the accelerated phase 4 months 
later with increasing number of BCR-
ABL copies. All of these 4 patients had 
lost all responses (HR and CyR) at the 
time of mutation analysis (Chahardouli 
et al. 2013). Apart from that, another 
study by Kim et al. showed that none 
of their chronic phase CML patients 
harboured T315I mutation while 8 
and 11 of them were in accelerated 
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and blast crisis respectively (Kim et 
al. 2009). In the present study, out of 
5 patients who had T315I mutation, 
only 2 patients were in accelerated 
phase/blast crisis at the time of analysis 
while the remaining 3 patients were 
in chronic phase of the disease. The 
lower number of patients harbouring 
T315I mutation in accelerated phase/
blast crisis might be due to the low 
sample size involved in this study. 
 In our study, the median OS of 
patients with T315I mutation was 
slightly longer than those without the 
mutation (Figure 2). There may be 
other factors that may contribute to 
this finding. For example, those who 
do not have T315I mutation might 
harbor other BCR-ABL mutation, 
such as E255K/V and Y253F/H (Kim 
et al. 2009), which were not tested in 
this study that can affect the OS. IM-
resistance can also occur in the absence 
of T315I mutation or any other kinase 
domain mutation although acquisition 
of mutation in the kinase domain is the 
most frequently identified mechanism 
of resistance (Vaidya et al. 2011). 
Another mechanism is presence of 
immature leukemia cells (stem cells) 
that may exhibit BCR-ABL independent 
mechanism of resistance. Previous 
study showed that these CML stem 
cell populations expressed high level 
of BCR-ABL mRNA, protein and kinase 
activity as well as elevated expression 
of IL-3 and G-CSF which cause these 
stem cells to be insensitive to IM as 
well as other TKI treatment (Jiang et al. 
2007). A number of cellular molecules 
that are involved in the regulation of 
drug uptake, drug metabolism or drug 
efflux may also influence the bio-
availability of TKI treatment (Wang et 
al. 2007).
CONCLUSION
Our study showed a higher prevalence 
of T315I mutation compared to other 
local studies although there were no 
significant differences in the baseline 
characteristics and disease phase 
between T315I and non-T315I mutated 
CML patients. However, median OS 
of those with T315I mutation was 
slightly longer than those without the 
mutation. This could be due to limited 
number of patients involved in this 
analysis. Further studies involving a 
larger number of patients are needed 
to confirm this. It would be useful 
to investigate other mutations in the 
BCR-ABL kinase domain in order to 
determine the cause of IM-resistance 
as presence of mutations in different 
regions of the kinase domain may lead 
to different levels of resistance. 
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